ArcherDX - About the company
ArcherDX is an acquired company based in Boulder (United States), founded in 2013 by John Iafrate. It operates as a Developer of molecular cancer diagnostic products. ArcherDX has raised $153M in funding from investors like Perceptive Advisors, Boulder Ventures and PBM Capital, with last known valuation of $*****. The company has 715 active competitors, including 162 funded and 126 that have exited. Its top competitors include companies like Natera, Guardant Health and LifeCell.
Company Details
Developer of molecular cancer diagnostic products. The company uses patented technology Anchored Multiplex PCR (AMP) for the development of in-vitro diagnostics (IVDs) and Personalized Cancer Monitoring (PCM) products for solid tumor biomarker identification. The company's product pipeline includes ArcherMET, NTRK CDx, and Fusion Plex.
- Website
- archerdx.com
- Social
- Email ID
- *****@archerdx.com
- Phone Number
- +1 **********
- Registered Address
- Boulder, Colorado
Key Metrics
Founded Year
2013
Location
Boulder, United States
Stage
Acquired
Total Funding
$153M in 3 rounds
Latest Funding Round
Last Known Valuation
$***** as on Jun 05, 2020
Investors
Ranked
37th among 715 active competitors
Employee Count
429 as on Dec 31, 2022
Investment & Acquisitions
Exit Details
Acquired by Invitae (Jun 22, 2020)
Legal entities associated with ArcherDX
ArcherDX is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
ARCHERDX, INC. CIN: 383944751 , United States, Active | Jun 27, 2013 | - | 429 (As on Dec 31, 2020) | - |
ArcherDX's acquisition details
Click here to take a look at ArcherDX's acquisition in detail
Sign up to download ArcherDX's company profile
ArcherDX's funding and investors
ArcherDX has raised a total funding of $153M over 3 rounds. Its first funding round was on Mar 20, 2018. Its latest funding round was a Series C round on Dec 17, 2019 for $*****. 9 investors participated in its latest round. ArcherDX has 10 institutional investors.
Here is the list of recent funding rounds of ArcherDX:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Dec 17, 2019 | 5975614 | Series C | 7539650 | 2149705 | 8061096 | 4335500 |
May 24, 2019 | 5148345 | Series B | 6226362 | 9596838 | 7513301 | |
Mar 20, 2018 | 1608048 | Series A | 5417109 | 7457693 |
Access funding benchmarks and valuations. Sign up today!View details of ArcherDX's funding rounds and investors
ArcherDX's founders and board of directors
Founder? Claim ProfileThe founders of ArcherDX is John Iafrate.
Here are the details of ArcherDX's key team members:
- John Iafrate: Co-Founder of ArcherDX. Contact Info: 1 email address
View details of ArcherDX's Founder profiles and Board Members
ArcherDX's employee count trend
ArcherDX has 429 employees as of Dec 22. The total employee count is 55.0% more than what it was in Dec 21. Here is ArcherDX's employee count trend over the years:
Uncover ArcherDX's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
ArcherDX's Competitors and alternates
Top competitors of ArcherDX include Natera, Guardant Health and LifeCell. Here is the list of Top 10 competitors of ArcherDX, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Natera 2004, Redwood City (United States), Public | Developer of cell-free DNA testing for oncology, women’s health, and organ health | $152M | 77/100 | |
2nd |  Guardant Health 2012, Redwood City (United States), Public | Developer of digital sequencing technology for cancer detection | $557M | 75/100 | |
3rd | A stem cell banking company specializing in cord blood and tissue preservation | $61.2M | 74/100 | ||
4th | Foundation Medicine 2010, Cambridge (United States), Acquired | Provider of genomics-based diagnostics test for cancer | $96.5M | 70/100 | |
5th | Online platform for genetic and diagnostic health testing that helps identify health risks | $67.6M | 69/100 | ||
6th | BillionToOne 2015, San Francisco (United States), Public | Provider of cell-free cancer liquid biopsy test | $389M | 69/100 | |
7th | Myriad Genetics 1991, United States, Public | Developer of molecular diagnostics and personalized medicine for cancer | - | 68/100 | |
8th | Caris Life Sciences 1996, Irving (United States), Public | Developer of panomic disease profiling technologies for cancer precision medicine | $1.23B | 66/100 | |
9th |  Foresight Diagnostics 2020, Aurora (United States), Acquired | Developer of minimally-invasive liquid biopsy test for the detection of cancer | $104M | 66/100 | |
10th | Qiagen 1984, Venlo (Netherlands), Acquired | Provider of products and reagents for molecular diagnostic assays | - | 65/100 | |
37th |  ArcherDX 2013, Boulder (United States), Acquired | Developer of molecular cancer diagnostic products | $153M | 54/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on ArcherDX's competitors? Click here to see the top ones
ArcherDX's Investments and acquisitions
ArcherDX has acquired Baby Genes. ArcherDX has not made any investments as of now.Reports related to ArcherDX
Here is the latest report on ArcherDX's sector:
News related to ArcherDX
Filter this list•
InterVenn Biosciences Welcomes Accomplished Diagnostics Executive Joshua Stahl as CEOBusiness Wire•Sep 27, 2023•InterVenn, ArcherDX
•
Integrated DNA Technologies acquires ArcherDX tech, Boulder facility in Invitae firesaleescapefromwithin.com•Dec 30, 2022•Integrated DNA Technologies, ArcherDX
•
Invitae Sells Archer NGS Research Assays to Integrated DNA Technologies for $48MGenomeWeb•Dec 20, 2022•Invitae, Dnatechindia, Integrated DNA Technologies, ArcherDX
•
Jury Awards ArcherDx, MGH $4.7M in Qiagen Patent Infringement LawsuitGenomeWeb•Aug 30, 2021•ArcherDX
•
Federal Court Rejects ArcherDx Motion Against Natera in Patent Infringement Lawsuit360Dx•Oct 05, 2020•Natera, ArcherDX
•
•
Natera Files Additional Patent Infringement Lawsuit Against ArcherDx360Dx•Aug 07, 2020•Natera, ArcherDX
•
ArcherDX and UCL extend TRACERx program collaboration to evaluate cancer evolutionInnovatioNews•Aug 03, 2020•ArcherDX
•
Lifshitz Law Firm, P.C. Announces Investigation of Benefytt Technologies, Inc., Delmarva Bancshares, Inc., Garrison Capital Inc., Portman Ridge Finance Corporation, Graf Industrial Corp., Invitae Corporation, Maxim Integrated Products, Analog Devices, Rexahn Pharmaceuticals, Inc., Vivint Solar, Inc. and Sunrun, Inc.PR Newswire•Jul 15, 2020•Lifshitz Law Firm, 1880 Bank, Portman Ridge, Invitae and 11 others
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about ArcherDX
Explore our recently published companies
- Superb Enterprises India - India based, 2008 founded, Unfunded company
- Slaney Healthcare - Ahmedabad based, Acquired company
- Surfers Mag - Germany based, Unfunded company
- Wugen - Funding Raised company
- NVS Communications - Funding Raised company
- Worldwide USD Markets - Funding Raised company
